Contegra pulmonary valved conduits cause no relevant hemolysis

Area of Science:

• Cardiovascular Surgery
• Pediatric Cardiology
• Biomaterials Science

Background:

• Contegra is a bovine jugular vein graft used for pediatric right ventricular outflow tract (RVOT) reconstruction.
• A phase I study protocol for FDA admission involved regular blood draws from the first 60 patients.
• Long-term follow-up (3.3 years) revealed no clinically significant hemolysis, prompting investigation into protocol changes.

Purpose of the Study:

• To evaluate the incidence of hemolysis in pediatric patients undergoing RVOT reconstruction with Contegra.
• To determine if Contegra grafts are associated with hemolysis and to assess the necessity of routine blood draws.

Main Methods:

• Analysis of blood samples (haptoglobin, free hemoglobin, reticulocytes, hemoglobin) from 60 pediatric patients (2 days to 17.4 years) over 132.6 years of follow-up.
• Development of a hemolysis score based on standardized parameter deviations.
• Comparison of pre- and postoperative values, with specific analysis of patients with mechanical valve prostheses.

Main Results:

• No association found between high free hemoglobin and lower hemoglobin, indicating absence of chronic hemolysis.
• RVOT gradient, a potential shear stress indicator, did not correlate with low haptoglobin or higher hemolysis scores.
• Postoperative hemolysis parameters normalized or trended toward normal, showing less hemolysis than preoperatively. Mechanical valve patients had significantly lower haptoglobin.

Conclusions:

• Contegra grafts do not appear to cause clinically relevant hemolysis in pediatric RVOT reconstruction.
• The findings support the removal of routine blood draws from the study protocol, reducing patient discomfort.